CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas

被引:3
|
作者
Gonzalez-Gomez, P
Bello, MJ
Alonso, ME
Lomas, J
Arjona, D
de Campos, JM
Vaquero, J
Isla, A
Lassaletta, L
Gutierrez, M
Sarasa, JL
Rey, JA
机构
[1] Univ Madrid, Hosp La Paz, Lab Oncogenet Mol, Dept Expt C, Madrid 28046, Spain
[2] Univ Madrid, Hosp La Paz, Dept Neurosurg, Madrid 28046, Spain
[3] Univ Madrid, Hosp La Paz, Dept Otolaryngol, Madrid 28046, Spain
[4] Univ Madrid, Hosp La Paz, Dept Pathol, Madrid 28046, Spain
[5] Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain
[6] Clin Puerta Hierro, Dept Neurosurg, Madrid, Spain
[7] Fdn Jimenez Diaz, Dept Pathol, E-28040 Madrid, Spain
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose of this research was to examine the DNA methylation profile of schwannomas. Experimental Design: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific PCR. Results: The most frequently methylated genes were THBS1 (36 %), p 73 (27 %), MGMT (20 %), NF2 and TIMP-3 (18%). The RB1/p16INK4a gene pair displayed aberrant methylayed alleles in 15% of cases, whereas methylation was relatively rare in the other genes (<5%). Methylation was tumor specific because it was absent in two nonneoplastic nerve sheath samples and two normeoplastic brain samples studied as controls. Conclusions: Our findings indicate that aberrant methylation seems to be a mechanism for NF2 gene inactivation, considered an early step in schwarmoma tumorigenesis, and as well, aberrant hypermethylation of other tumor-related genes might represent secondary events that also contribute to the development of these tumors.
引用
收藏
页码:5601 / 5606
页数:6
相关论文
共 50 条
  • [41] Aberrant CpG island methylation in AML is associated with disease progression and relapse.
    Kroeger, Heike
    Jelinek, Jaroslav
    Bueso-Ramos, Carlos E.
    Issa, Jean-Pierre J.
    BLOOD, 2006, 108 (11) : 170A - 170A
  • [42] CpG island methylation and expression of tumour-associated genes in lung carcinoma
    Dammann, R
    Strunnikova, M
    Schagdarsurengin, U
    Rastetter, M
    Papritz, M
    Hattenhorst, UE
    Hofmann, HS
    Silber, RE
    Burdach, S
    Hansen, G
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (08) : 1223 - 1236
  • [43] Elevated CpG island methylation of GCK gene predicts the risk of type 2 diabetes in Chinese males
    Tang, Linlin
    Ye, Huadan
    Hong, Qingxiao
    Wang, Lingyan
    Wang, Qinwen
    Wang, Hongwei
    Xu, Leiting
    Bu, Shizhong
    Zhang, Lina
    Cheng, Jia
    Liu, Panpan
    Le, Yanping
    Ye, Meng
    Mai, Yifeng
    Duan, Shiwei
    GENE, 2014, 547 (02) : 329 - 333
  • [44] Allele-specific methylation at the promoter-associated CpG island of mouse Copg2
    Jihye Yun
    Chang Won Park
    Young Jae Lee
    Jae Hoon Chung
    Mammalian Genome, 2003, 14 : 376 - 382
  • [45] Allele-specific methylation at the promoter-associated CpG island of mouse Copg2
    Yun, J
    Park, CW
    Lee, YJ
    Chung, JH
    MAMMALIAN GENOME, 2003, 14 (06) : 376 - 382
  • [46] Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells
    Rice, JC
    Massey-Brown, KS
    Futscher, BW
    ONCOGENE, 1998, 17 (14) : 1807 - 1812
  • [47] Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells
    Judd C Rice
    Kathy S Massey-Brown
    Bernard W Futscher
    Oncogene, 1998, 17 : 1807 - 1812
  • [48] Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas
    Welling, DB
    Guida, M
    Goll, F
    Pearl, DK
    Glasscock, ME
    Pappas, DG
    Linthicum, FH
    Rogers, D
    Prior, TW
    HUMAN GENETICS, 1996, 98 (02) : 189 - 193
  • [49] BRCA1/2-Associated and Sporadic Breast Cancers: Fellow Travelers or Not?
    Garber, Judy E.
    CANCER PREVENTION RESEARCH, 2009, 2 (02) : 100 - 103
  • [50] Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development
    Fuse, Marisa A.
    Dinh, Christine T.
    Vitte, Jeremie
    Kirkpatrick, Joanna
    Mindos, Thomas
    Plati, Stephani Klingeman
    Young, Juan I.
    Huang, Jie
    Carlstedt, Annemarie
    Franco, Maria Clara
    Brnjos, Konstantin
    Nagamoto, Jackson
    Petrilli, Alejandra M.
    Copik, Alicja J.
    Soulakova, Julia N.
    Bracho, Olena
    Yan, Denise
    Mittal, Rahul
    Shen, Rulong
    Telischi, Fred F.
    Morrison, Helen
    Giovannini, Marco
    Liu, Xue-Zhong
    Chang, Long-Sheng
    Fernandez-Valle, Cristina
    NEURO-ONCOLOGY, 2019, 21 (04) : 486 - 497